Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Aptera Motors Suspends ATM Prospectus, Reports $9.2M Cash Estimate

Aptera Motors Corp. filed a Form 8-K on November 10, 2026, disclosing the suspension and termination of its at-the-market offering prospectus and providing preliminary cash figures for the quarter ended September 30, 2026.

Anjali Anand | 10 November 2026

PepGen Phase 2 FREEDOM2-DM1 10mg/kg Data and Q3 2026 Results

PepGen Inc. filed a current report on November 10, 2026, disclosing third quarter 2026 financial results and announcing positive Phase 2 FREEDOM2-DM1 data from its 10mg/kg multiple ascending dose cohort.

Aakashdeep | 10 November 2026

NantWorks Exercises Warrants for 17.7M PDS Biotech Shares

PDS Biotechnology Corporation filed a Form 8-K on November 10, 2026, disclosing that NantWorks exercised outstanding common stock warrants to purchase an aggregate of 17,699,115 shares of common stock at an exercise price of $0.22 per share, generating approximately $3.9 million in gross proceeds …

Aakashdeep | 10 November 2026

Paul J. Hastings Files Initial Ownership Statement at Azora Therapeutics

Paul J. Hastings submitted an initial statement of beneficial ownership with the SEC on November 10, 2026, in connection with an event date of November 3, 2026, disclosing his status as a director of Azora Therapeutics, Inc. (DE), listed on NASDAQ:AZR.

Anjali Anand | 10 November 2026

Atossa Therapeutics Q3 2026: $20.6M Cash, $23.7M Nine-Month Loss

Atossa Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a net loss of $23.718 million for the nine months ended September 30, 2026, with cash and cash equivalents of $20.574 million at quarter end.

Aditi Sarkar | 10 November 2026

Nanox Board Approves 25%-30% Operating Expense Cut Plan

Nano-X Imaging Ltd filed a Form 6-K with the SEC on November 9, 2026, disclosing that its Board of Directors approved a strategic realignment and efficiency plan targeting a 25%-30% annualized reduction in operating expenses, alongside a global workforce reduction and four renewed strategic …

Aakashdeep | 10 November 2026

Nova CFO to Speak at Two Investor Conferences in November-December 2026

Nova Ltd. filed a Form 6-K on November 10, 2026, announcing that Chief Financial Officer Guy Kizner will participate in two investor conferences during November and December 2026.

Shwetambri Chauhan | 10 November 2026

Aida Habtezion Files Initial Ownership Statement With Azora Therapeutics

Director Aida Habtezion filed a Form 3 Initial Statement of Beneficial Ownership with the SEC on November 10, 2026, reporting her initial ownership position in Azora Therapeutics, Inc. as of the event date of November 3, 2026.

Anjali Anand | 10 November 2026

Thomas M. Soloway Files Initial Ownership Statement at Azora Therapeutics

Thomas M. Soloway, a newly reported director at Azora Therapeutics, Inc., filed a Form 3 Initial Statement of Beneficial Ownership with the SEC on November 10, 2026, reflecting an event date of November 3, 2026.

Aakashdeep | 10 November 2026

Why Is Bluejay Diagnostics (NASDAQ:BJDX) Dropping 9.24% Pre-Market on Tuesday?

The release gave no reason for the split and no Nasdaq deficiency details, so the motive is not confirmed. As general context, companies often use reverse splits to lift the share price above the USD 1.00 minimum bid that Nasdaq requires, yet the split …

Vinay Lochav | 10 November 2026
Support

Hi! How can we help you today?

Loading…